Loading…
Loading…
This exchange-traded fund allocates capital to pioneering enterprises reshaping medical detection, treatments, and care delivery, encompassing areas from genetic manipulation to automated surgical procedures and online health ecosystems.
Is FMED's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Exchange-traded fund (ETF) inflows reached an astonishing $1 trillion for the first half of 2026 alone, the latest sign that investors everywhere are continuing to lean heavily on these vehicles to simplify their experience and add built-in diversification to their portfolios. Unsurprisingly, the number of funds available continues to skyrocket, although many investors stick with major ETFs tracking the S&P or other prominent indexes instead of venturing into unique strategies.
While healthcare stocks may not always seem the most enticing, they've quietly surged over the last month. The active healthcare tech ETF, FMED, which focuses on industry disruptors, saw its June performance significantly leapfrog its overall YTD numbers.
An aging population is leading to a profound demographic shift known as the “Silver Tsunami.” With more Baby Boomers reaching retirement age, the demand for senior living facilities and medicinal innovation is increasing.
Like many sectors, the healthcare industry is poised for disruption from artificial intelligence (AI) technology, which may create an investment opportunity for the Fidelity Disruptive Medicine ETF (FMED). Marred by regulatory scrutiny and rising costs, the healthcare sector overall has had its fair share of challenges in 2025.
Healthcare has been the worst-performing sector in the S&P 500 this year. But when it comes to unlocking potential capital growth ahead, that may not be all bad news.